Next generation precision medicines drive better patient outcomes
Next generation digital, clinical, and financial solutions will make them accessible
Why this matters
Tremendous advancements in our ability to harness the body’s natural defense mechanisms have placed potentially curative therapies within our reach. Outdated processes and technology may allow these opportunities to elude us. If we do not seize these opportunities, progress will stagnate, and it is imperative that we advance.
12 years
since Emily Whitehead was cured of leukemia with CAR-T
FDA approved cell and gene therapy products
of addressable patients who can access CAR-T therapy
What you can do
By baking in data sharing and interoperability to the protocol design, demonstrating the feasibility of at-scale manufacturing early in development, and accepting and planning the inherent variability in the process.
By investing in digital capabilities to help assess the process. Leverage analytics and automation to streamline manufacturing for optimal results.
What’s trending in Advanced Therapies
Our leader
Sanjay Srivastava, Ph.D
Managing Director – Life Sciences, Cell and Gene Lead